Terlipressin for hepatorenal syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Gluud, Lise Lotte ^a   Kjaer, M S ^b   Christensen, E ^b  

^a University of Copenhagen   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CIMETIDINE; CREATININE; DOPAMINE; FRESH FROZEN PLASMA; OCTREOTIDE; PLACEBO; TERLIPRESSIN;

ABDOMINAL PAIN; ATTRIBUTABLE RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA ANALYSIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HEART ARRHYTHMIA; HEPATORENAL SYNDROME; HUMAN; HYPERTENSION; INFORMATION PROCESSING; INFORMATION RETRIEVAL; KIDNEY FUNCTION; MORTALITY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; URINE VOLUME;

EID: 42749099661     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005162.pub2     Document Type: Review

References (51)

1. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. Journal of Hepatology 1998;29:565-70.
2. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43.
3. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. Journal of Gastroenterology and Hepatology 2003;18:152-6.
4. Yang YZ, Dan ZL, Liu NZ, Liu M, et al. [Efficacy of terlipressin in treatment of liver cirrhosis with hepatorenal syndrome]. Journal of Internal Intensive Medicine 2001;7:123-5.
5. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. European Journal of Gastroenterology & Hepatology 2002;14:1363-8.
6. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
7. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. Journal of Gastroenterology and Hepatology 2002;17:882- 8.
8. Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, et al. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepato-Gastroenterology 2003;50:303-5.
9. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80.
10. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire L, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-12.
11. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
12. Gulberg V, Luppa P, Pauletzki J, Paumgartner G, Gerbes AL. Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin. Zeitschrift für Gastroenterologie 1998;36:1053-8.
13. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5.
14. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, diMartino V, et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. European Journal of Gastroenterology & Hepatology 2002;14:153-8.
15. Kaffy F, Borderie C, Chagneau C, Ripault MP, Larzilliere I, Silvain C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. Journal of Hepatology 1999;30:174.
16. Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrology, Dialysis, Transplantation 2005;20:1813-20.
17. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30.
18. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastro-Enterologica Belgica 2001;64:15-9.
19. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-8.
20. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. Journal of Hepatology 2002;40:40-6.
21. Salo J, Gines A, Quer JC, Fernandez-Esparrach G, Guevara M, Gines P, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. Journal of Hepatology 1996;25:916-23.
22. Saner F, Kavuk I, Lang H, Biglarnia R, Fruhauf NR, Schafers RF, et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. European Journal of Medical Research 2004;9:78-82.
23. Shawcross DL, Davies NA, Mookerjee RP, Hayes PC, Williams R, Lee A, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004;39:471-5.
24. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. Journal of Hepatology 2000;33:43-8.
25. Terlipressin as treatment of patients with cirrhosis and hepatorenal syndrome. Effect on survival and renal function. Multicenter, randomised and prospective study.. Ongoing study - February 2002.
26. Double-blind, randomised, placebo controlled trial of terlipressin for the treatment of type 1 hepatorenal syndrome.. Ongoing study - Not reported (enrolling patients July 2007)..
27. A double-blind, randomised, placebo-controlled, multicentre phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1.. Ongoing study - June 2004.
28. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascitis and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76.
29. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. Journal of Hepatology 2000;32:157-70.
30. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. American Journal of Gastroenterology 2005;100:631-5.
31. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95.
32. Cardenas A, Arroyo V. Hepatorenal syndrome. Annals of Hepatology 2003;2:23-9.
33. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet 1982;2:66-8.
34. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993;105:229-36.
35. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47.
36. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-27.
37. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology 2006;163:493-501.
38. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-termsurvival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991;51:428-30.
39. Gulberg V, Gerbes AL. TIPS or vasoconstrictors for the treatment of hepatorenal syndrome type 1- effect on survival? [TIPS oder vasokonstriktoren beim hepatorenalen syndromtyp 1 - beeinflussen sie das patientenüberleben?] . Zeitschrift für Gastroenterologie 2002;40:823-6.
40. Ioannou GN, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD002147. DOI:10.1002/14651858.CD002147.
41. Kjaergard LL, Villumsen J, Gluud C. Reportedmethodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
42. Lin HC, Yang YY, Hou MC, Huang YT, Lee WC, Lee FY, et al. Hemodynamic effects of a combination of octreotide and terlipressin in patients with viral hepatitis related cirrhosis. Scandinavian Journal of Gastroenterology 2002;37:482-7.
43. Medel J, Boccara G, Van de Steen E, Bertrand M, Godet G, Coriat P. Terlipressin for treating intraoperative hypotension: can it unmask myocardial ischemia?. Anesthesia and Analgesia 2001;93:53-5.
44. Moller S, Henriksen JH. Review article: pathogenesis and pathophysiology of hepatorenal syndrome - is there scope for prevention?. Alimentary Pharmacology & Therapeutics 2004;20:31-41.
45. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004;24:1050-3.
46. Pasqualetti P, Festuccia V, Collacciani A, Acitelli P, Casale R. Circadian rhythm of arginine vasopressin in hepatorenal syndrome. Nephron 1998;78:33-7.
47. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
48. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
49. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439-47.
50. Seu P, Wilkinson AH, Shaked A, Busuttil RW. The hepatorenal syndrome in liver transplant recipients. American Surgeon 1991;57:806-9.
51. Shawcross DL, Davies NA, Mookerjee RP, Hayes PC, Williams R, Lee A, et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 2004;39:471-5.